Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
Article in Frontiers in Public Health (February 2024)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
Article in Frontiers in Public Health (February 2024)
Article in Clinical Medicine Insights Oncology (January 2024)
Article in Cancer Research and Clinic (August 2023)